MM
Therapeutic Areas
LianBio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Approved (China NMPA Review) |
| TP-03 (lotilaner) | Demodex Blepharitis | Phase 3 |
| NBTXR3 | Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 |
| Infigratinib | Cholangiocarcinoma | Phase 2 |
| LYT-100 (deupirfenidone) | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 |
| Tunnel Program | Undisclosed Gastrointestinal Targets | Pre-clinical |
Leadership Team at LianBio
KP
Konstantin Poukalov
Executive Director and Interim Chief Executive Officer
YL
Yi Larson
Chief Financial Officer
DY
Debra Yu, M.D.
Former Chief Executive Officer and Director
JP
Jeff Poulton
Former Chief Financial Officer
YW
Yizhe Wang, Ph.D.
Chief Scientific Officer
SW
Sizhen Wang
General Manager, China
MH
Michael Humphries
Chief Business Officer
PK
Perry Karsen
Chairman of the Board of Directors
AS
Alice Shaw, M.D., Ph.D.
Director
JB
James B. Tananbaum, M.D.
Director